ReviewJournal of ovarian research2015
Use of aromatase inhibitors in practice of gynecology.
Review in Journal of ovarian research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 38 citations in OpenAlex.
- Endometriosis-associated bone loss: re-evaluating the potential role of systemic inflammation and hypoestrogenic therapies.Frontiers in global women's health · 2026Review
- Estrogen levels in young women with hormone receptor-positive breast cancer on ovarian function suppression therapy.NPJ breast cancer · 2024Article
- PCOS and vitamin D: a clinical appraisal.Archives of gynecology and obstetrics · 2024Review
- A comprehensive review on the impact of calcium and vitamin D insufficiency and allied metabolic disorders in females.Food science & nutrition · 2023Review
- MiR-195-5p suppresses gastric adenocarcinoma cell progression via targeting OTX1.Histology and histopathology · 2023Article
- Aromatase inhibition increases blood pressure and markers of renal injury in female rats.American journal of physiology. Renal physiology · 2022Article
- PCOS Physiopathology and Vitamin D Deficiency: Biological Insights and Perspectives for Treatment.Journal of clinical medicine · 2022Review
- Antioxidative, Anti-Inflammatory, Anti-Obesogenic, and Antidiabetic Properties of Tea Polyphenols-The Positive Impact of Regular Tea Consumption as an Element of Prophylaxis and Pharmacotherapy Support in Endometrial Cancer.International journal of molecular sciences · 2022Review
- Estrogen disorders: Interpreting the abnormal regulation of aromatase in granulosa cells (Review).International journal of molecular medicine · 2021Review
- Estrogen Receptors in Polycystic Ovary Syndrome.Cells · 2021Review
- Dynamics and Mechanism of Binding of Androstenedione to Membrane-Associated Aromatase.Biochemistry · 2020Article
- Structural Recognition and Binding Pattern Analysis of Human Topoisomerase II Alpha with Steroidal Drugs: In Silico Study to Switchover the Cancer Treatment.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Long Non-Coding RNAs as New Master Regulators of Resistance to Systemic Treatments in Breast Cancer.International journal of molecular sciences · 2018Review
- Reversal of tubo-ovarian atypical epithelial patterns after cessation of ovarian stimulation by letrozole.International journal of experimental pathology · 2016Article
- Effect of Aromatase Inhibitors on Serum Calprotectin Levels in an Animal Experimental Model: Trial.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe conversion of androgens into estrogens by aromatase is called aromatization and is inhibited by aromatase inhibitors (AIs). The aim of this article is to evaluate the use of aromatase inhibitors in gynecological diseases such as endometriosis, leiomyoma, estrogen- dependent gynecologic neoplasia and infertility.
methodsThis is a review of literature combined with experience and use of aromatase inhibitors ın practıce of gynecology.
conclusionAIs are promising agents in treatment of estrogen dependent disease. However lack of experience, side effects and cost are limiting factors for using these agents in infertility treatment. However there is need for larger, well designed randomized trials to generate robust data in order to establish the true potential of aromatase inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.